A firmly estblished and well tolerated angiotensin-coverting enzyme inhibitor. It attenuates the myocardial infarction induced rise in cardiac cytokine expression. Clinical trials show that quinapril prevents restenosis after coronary stenting in patients with angiotensin-coverting enzyme D allele.
PRODUCT PROPERTIES |
Formula: | | C25H30N2O5 . HCl |
MW: | | 474.99 |
CAS: | | 82586-55-8 |
MI: | | 13: 8139 |
Purity: | | ≥98% |
Solubility: | | Soluble in water (31mg/mL). |
Long Term Storage: | | Ambient |
|
|
|
Product Literature References
Effects of quinapril on myocardial function, ventricular remodeling and cardiac cytokine expression in congestive heart failure in the rat: G.C. We, et al.; Cardiovasc.Drugs Ther.
16, 29 (2002),
Abstract;
Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale: J.W. Warnica, et al.; Can. J. Cardiol.
18, 1191 (2002),
Abstract;
Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders: C.R. Culy and B. Jarvis; Drugs
62, 339 (2002),
Abstract;